- Previous Close
3.3000 - Open
3.5000 - Bid 4.2500 x --
- Ask 4.3800 x --
- Day's Range
3.4700 - 5.1000 - 52 Week Range
3.0700 - 7.6400 - Volume
171,355 - Avg. Volume
20,025 - Market Cap (intraday)
156.027M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2900 - Earnings Date Aug 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.38
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
www.eupraxiapharma.com29
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: EPRX.TO
View More
Performance Overview: EPRX.TO
Trailing total returns as of 2024-11-01, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EPRX.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EPRX.TO
View MoreValuation Measures
Market Cap
117.55M
Enterprise Value
91.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-98.68%
Return on Equity (ttm)
-314.41%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27M
Diluted EPS (ttm)
-1.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
23.32M
Total Debt/Equity (mrq)
34.94%
Levered Free Cash Flow (ttm)
-14.62M